Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04007029 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04007029 · ClinicalTrials.gov record · last posted 2026-08-20

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

StatusActive, Not Recruiting
PhasePhase 1
Started2019-10-04
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase I trial studies the side effects and best dose of CD19/CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see how effective they are in treating patients with non-Hodgkin's B-cell lymphoma or chronic lymphocytic leukemia that has come back (recurrent) or has not responded to treatment (refractory). In CAR-T cell therapy, a patient's white blood cells (T cells) are changed in the laboratory to produce an engineered receptor that allows the T cell to recognize and respond to CD19 and CD20 proteins. CD19 and CD20 are commonly found on non-Hodgkin?s B-cell lymphoma and chronic lymphocytic leukemia cells. Chemotherapy drugs such as fludarabine phosphate and cyclophosphamide can control cancer cells by killing them, by preventing their growth, or by stopping them from spreading. Combining CD19/CD20 CAR-T cells and chemotherapy may help treat patients with recurrent or refractory B-cell lymphoma or chronic lymphocytic leukemia.

Protocol amendment history 2 changes detected by DataLookout

2026-08-21
Primary completion pushed: 2026-08-01 → 2027-08-01
2026-08-21
Completion pushed: 2027-08-01 → 2028-08-01
Trial Details
NCT Number NCT04007029
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Parker Institute for Cancer Immunotherapy
Conditions CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma +6 more
Enrollment 24 participants
Start Date 2019-10-04
Primary Completion 2027-08-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-20